38937-66-5
38937-66-5 结构式
基本信息
次异羟肟酸
辛烷-1,8-二氧肟酸
N1,N8-二羟基辛烷二酰胺
SBHA
[PTYR705]-STAT3
STAT3 (PTYR705)
SUBEROHYDROXAMIC ACID
SUBERIC BISHYDROXAMATE
SuberohydroxaMic acid 95%
SuberoylBis-hydroxamicAci
suberic bishydroxamic acid
SUBEROYL BISHYDROXAMIC ACID
常见问题列表
| Target | Value |
|
HDAC1
(Cell-free assay) | 0.25 μM |
|
HDAC3
(Cell-free assay) | 0.3 μM |
Suberoyl bis-hydroxamic acid (10, 20 or 50 μM; 24 hours) combination with TRAIL improves apoptosis extent, and when TRAIL is combined with 20 μM SBHA (itself causing only 10–15% apoptosis), resulting in 45–50% cell death.Suberoyl bis-hydroxamic acid (20-50 μM; 10-20 hours) alone has little effect on the expression of the proteins Bcl-xL, Mcl-1, and has albeit mildeffect on Bax. When it combines with TRAIL,which increases the ratio of relative protein expression of Bcl-xL and Bax in early periods, while the change in the ratio of Mcl-1 and Bax increases later in MM-BI and Ist-Mes2 cells.Suberoyl bis-hydroxamic acid (30 μM; 6 hours) causes accumulation of acetylated histone H4 in MEL cells.
Apoptosis Analysis
| Cell Line: | MM-BI and Ist-Mes2 cells |
| Concentration: | 10 μM, 20 μM or 50 μM |
| Incubation Time: | 24 hours |
| Result: | Showed a cooperative effect in cell apoptosis. |
Suberoyl bis-hydroxamic acid (intraperitoneal injection; 200 mg/kg; every 2 days; 12 days) reveals a marked increase in the active form of Notch1 (NICD) with a concomitant decrease in ASCL1. It reduces the MTC tumor growth.
| Animal Model: | Nude mice injected with human MTC cells |
| Dosage: | 200 mg/kg |
| Administration: | Intraperitoneal injection; every 2 days; 12 days |
| Result: | Resulted in an average 55% inhibition of tumor growth in SBHA treatment group. |